# Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

> **NCT00001677** · PHASE2 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 40 (—)

## Conditions studied

- Arthritis, Rheumatoid
- Synovitis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT00001677
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** —
- **Final completion:** 2000-04
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001677, "Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00001677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*